Clinical Trial Update: Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 ocular gene transfer study for X-linked retinoschisis (RS1) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• X-linked Retinoschisis

Drugs mentioned

• RS1 ocular gene transfer (AAV-RS1 gene therapy)

Snippet

Sponsor: VegaVect, Inc. | Conditions: Retinoschisis, X-Linked | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-02-14